Eli Lilly and Company (NYSE:LLY) Shares Down 3.2% – Here’s Why

Eli Lilly and Company (NYSE:LLY)’s share price dropped 3.2% on Monday . The stock traded as low as $1,013.00 and last traded at $1,017.9670. Approximately 3,079,183 shares traded hands during mid-day trading, a decline of 9% from the average daily volume of 3,366,631 shares. The stock had previously closed at $1,051.99.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The company said it is preparing to launch its oral obesity drug, orforglipron, in the U.S. as soon as Q2 if it receives FDA approval, which would add a major new revenue stream. Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
• Positive Sentiment: CHMP has backed expanding Olumiant’s use to adolescents with severe alopecia areata, which should widen EU market opportunity ahead of a formal EU approval decision. LLY Wins CHMP Nod for Olumiant’s Expanded Use in Alopecia Areata
• Positive Sentiment: Institutional filings show continued accumulation by “smart money” during the recent pullback, indicating confidence from large holders. What Smart Money Loves About Lilly
• Positive Sentiment: Analyst coverage remains favorable overall (average recommendation around “Moderate Buy”), supporting sentiment that the company is broadly well-regarded by sell-side analysts. Eli Lilly and Company (NYSE:LLY) Receives Average Recommendation of “Moderate Buy” from Analysts
• Neutral Sentiment: Industry research notes Lilly as a large-cap name to retain as the pharma sector shows signs of recovery—supportive but not an immediate catalyst. 4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
• Neutral Sentiment: CEO David Ricks cautioned that AI isn’t yet solving complex biology/chemistry questions on its own—an operational comment that tempers hype but doesn’t change near-term commercial prospects. Tech giants see a cure for cancer in AI. But Eli Lilly’s CEO finds it ‘not particularly good’ at solving biology or chemistry problems
• Negative Sentiment: Competitor Novo Nordisk is expanding manufacturing in Ireland to bolster capacity for oral medicines, a move that strengthens Novo’s ability to meet demand and increases competitive pressure in the obesity/GLP-1 market. Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly
• Negative Sentiment: Several commentary pieces highlight Lilly’s steep valuation after large recent gains and suggest investors consider cheaper alternatives—these narratives can amplify profit-taking and weigh on the stock. Up Over 400% in 5 Years, Is It Too Late to Invest in Eli Lilly Stock?
• Negative Sentiment: Articles urging investors to favor high-yield alternatives over Lilly emphasize the stock’s rich price multiples, which can discourage new entrants and cap upside near-term. Should You Forget Eli Lilly and Buy This Magnificent High-Yield Dividend Stock Instead?

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. TD Cowen increased their price objective on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Morgan Stanley raised their price objective on shares of Eli Lilly and Company from $1,290.00 to $1,313.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Zacks Research lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Finally, Leerink Partners increased their target price on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,229.59.

Eli Lilly and Company Trading Down 3.2%

The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The firm has a market capitalization of $960.31 billion, a price-to-earnings ratio of 44.36, a P/E/G ratio of 1.22 and a beta of 0.40. The business has a fifty day moving average price of $1,053.15 and a 200 day moving average price of $931.94.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter in the previous year, the business earned $5.32 EPS. The company’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 30.15%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Brighton Jones LLC increased its holdings in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its position in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares in the last quarter. OneAscent Wealth Management LLC increased its stake in shares of Eli Lilly and Company by 32.0% in the second quarter. OneAscent Wealth Management LLC now owns 359 shares of the company’s stock worth $280,000 after buying an additional 87 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in Eli Lilly and Company by 19.0% in the second quarter. Sequoia Financial Advisors LLC now owns 140,201 shares of the company’s stock valued at $109,291,000 after acquiring an additional 22,410 shares in the last quarter. Finally, Schnieders Capital Management LLC. boosted its stake in Eli Lilly and Company by 16.7% during the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after acquiring an additional 1,141 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.